The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin

Nephrology Dialysis Transplantation

Volumn 14, Issue 8, 1999, Pages 1836-1841

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN;

EDITORIAL; ERYTHROPOIESIS; KIDNEY FAILURE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG INTERACTIONS; EPOETIN ALFA; ERYTHROPOIESIS; HEMATINICS; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0032792965     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.8.1836     Document Type: Editorial

References (28)

1. Sennesael J, Verbeelen D. Therapeutic efficacy and tolerance of two orally active angiotensin converting enzyme inhibitors in patients undergoing regular hemodialysis. Kidney Int 1985; 28: A252
2. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30: 659-664
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
4. Gavras H, Gavras I. Angiotensin converting enzyme inhibitors: properties and side effects. Hypertension 1988; 11 [Suppl II]: 37-41
5. Weber MA. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. Am J Med 1988; 84 [Suppl 4A]: 16-23
6. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 1984; 4: 355-360
7. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991; 17: 199-205
8. Walter J. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? Nephrol Dial Transplant 1993; 8: 1428
9. Hess E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 1996; 11: 749-751
10. Erturk S, Ates K, Duman N, Karatan O, Erbay B, Ertug E. Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: possible implications of angiotensin converting enzyme inhibitors. Nephrol Dial Transplant 1996; 11: 396-397
11. Matsumura M, Nomura H, Koni I, Mabuchi H. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Nephron 1997; 77: 164-168
12. Albitar S, Genin R, Fen-Chong M, Serveaux M-O, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210
13. Ertürk S, Nergizoglu G, Ates K et al. The impact of weaning of ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 1912-1916
14. Conlon PJ, Albers F, Butterly D, Schwab SJ. ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 1358
15. Sánchez JA. ACE inhibitors do not decrease r-HuEPO response in patients with end-stage renal failure. Nephrol Dial Transplant 1995; 10: 1476-1477
16. Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Am J Kidney Dis 1996; 28: 535-540
17. Chew CG, Weise MD, Disney APS. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrol Dial Transplant 1999; 2047-2049
18. Schiffl H, Lang SM. Angiotensin-converting enzyme inhibitors but not angiotensin II AT1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease. Nephron 1999; 81: 106-108
19. Vlahakos DV, Balodimos C, Papachristopoulos V, Vassilakos P, Hinari E, Vlachojannis JG. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin Nephrol 1995; 43: 53-59
20. Kamper A-L, Nielsen OJ. Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 1990; 50: 611-618
21. Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of post-transplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26: 495-500
22. Suh B, Suh J, Kwun K. Effect of captopril in the treatment of erythrocytosis after renal transplantation. Transplant Proc 1996; 28: 1557-1558
23. Kupin W, Venkat KK, Goggins M, Abouljoud M, Escobar F, Mozes M. Benefit of angiotensin II receptor blockade in the treatment of post-transplant polycythemia in renal transplant recipients. Transplant Proc 1997; 29: 207-208
24. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-2314
25. Azizi M, Rousseau A, Ezan E et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97: 839-844
26. Morrone LF, Di Paolo S, Logoluso F et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 1997; 64: 913-918
27. Constantinescu CS, Goodman DB, Ventura ES. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998; 62: 25-31
28. Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10: 607-614